SLC5A2 and diabetes mellitus: Selective SGLT-2 inhibitors, such as empagliflozin, dapagliflozin or canagliflozin, used in the treatment of diabetes, have a unique mechanism of action independent of both the effect on insulin production and the effect on insulin sensitivity.